Akihiro Yoshitake

Akihiro Yoshitake

Auto-generated profile, based on publicly available information

Akihiro Yoshitake

Department of Cardiovascular Surgery, Saitama Medical University International Medical Center, Saitama, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
AYAkihiro Yoshitake
Akihiro Yoshitake
MTMasato Tochii
Masato Tochii
CTChiho Tokunaga
Chiho Tokunaga
JHJun Hayashi
Jun Hayashi
ATAkitoshi Takazawa
Akitoshi Takazawa
TAToshihisa Asakura
Toshihisa Asakura
OBJECTIVES: We evaluated the operative and long-term outcomes of the frozen elephant trunk (FET) technique for acute type A aortic dissection. METHODS: This study evaluated 426 consecutive patients who underwent aortic repair for acute type A aortic dissection from June 2007 to December 2018 at our centre. Of these, 139 patients underwent total arch replacement with FET (FET group), and 287 underwent other procedures (no FET group). Ninety-two patients in the FET group were matched to 92 patients in the no FET group by using propensity score matching analysis. RESULTS: Thirty-day mortality and neurological dysfunction were not significantly different between the FET and no FET groups (1.4% vs 2.4%, P = 0.50 and 5.0% vs 6.3%, P = 0.61, respectively). Long-term survival was better in the FET group than in the no FET group (P = 0.008). Freedom from distal thoracic reintervention was similar in the FET and no FET groups (P = 0.74). In the propensity-matched patients, freedom from aortic-related death was better in the FET group than in the no FET group (P = 0.044). CONCLUSIONS: Operative outcomes showed no significant difference between the 2 groups. FET contributes to better long-term survival in patients with acute type A aortic dissection.

1 October 2016 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
AYAkihiro Yoshitake
Akihiro Yoshitake
THTakashi Hachiya
Takashi Hachiya
KOKazuma Okamoto
Kazuma Okamoto
HKHiroto Kitahara
Hiroto Kitahara
SKShinji Kawaguchi
Shinji Kawaguchi
HSHideyuki Shimizu
Hideyuki Shimizu

1 November 2007 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
AYAkihiro Yoshitake
Akihiro Yoshitake
AMAtsuo Mori
Atsuo Mori
HSHideyuki Shimizu
Hideyuki Shimizu
TUToshihiko Ueda
Toshihiko Ueda
NKNobuyuki Kabei
Nobuyuki Kabei
RYRyohei Yozu
Ryohei Yozu

18 February 2022 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
CTChiho Tokunaga
Chiho Tokunaga
YKYu Kumagai
Yu Kumagai
FCFumiya Chubachi
Fumiya Chubachi
YHYuto Hori
Yuto Hori
ATAkitoshi Takazawa
Akitoshi Takazawa
AYAkihiro Yoshitake
Akihiro Yoshitake
OBJECTIVES: Total arch replacement (TAR) using an endovascular approach has been initially introduced as the frozen elephant trunk technique (FET). In our institute, TAR using the FET with Frozenix has been used as the first-line treatment for distal aortic arch aneurysms since 2014. This study aimed to evaluate the early and long-term outcomes and demonstrate the efficacy of this procedure. METHODS: Between 2014 and 2021, 121 consecutive patients were treated with TAR using the FET with Frozenix for distal aortic arch aneurysms. Early and long-term outcomes were retrospectively analysed. RESULTS: The 30-day mortality rate was 2.5% (3/121). Of postoperative complications, paraplegia due to spinal cord injury occurred in 2 (1.7%) patients, stroke in 12 (9.9%) and acute renal failure in 10 (8.3%). At follow-up, 23 secondary aortic interventions were required and 8 (6.6%) patients underwent intended secondary thoracic endovascular aortic repair for residual descending aortic aneurysm. Late and aortic-related deaths occurred in 16 (13.2%) and 4 (3.3%) patients, respectively. The overall long-term survival rates at 1, 3 and 5 years were 87.6%, 83.1% and 65.4%, respectively, while the rates of freedom from aortic-related death at 1, 3 and 5 years were 95.7%, 95.7% and 84.8%, respectively. CONCLUSIONS: TAR using the FET with Frozenix for distal aortic arch aneurysms has acceptable early mortality and morbidity. Spinal cord injury and paraplegia occur less frequently than previously reported. The technique has satisfactory long-term survival and freedom from aortic-related death.

1 January 2013 in Annals of Vascular Diseases
Verified
Journal Article
Open access
KSKawaguchi Satoshi
Kawaguchi Satoshi
HSHideyuki Shimizu
Hideyuki Shimizu
AYAkihiro Yoshitake
Akihiro Yoshitake
TSTaro Shimazaki
Taro Shimazaki
TIToru Iwahashi
Toru Iwahashi
RYRyohei Yozu
Ryohei Yozu
Stent-grafts for endovascular repair of thoracic aortic aneurysms have been commercially available for more than ten years in the West, whereas, in Japan, a manufactured stent-graft was not approved for the use until March 2008. Nevertheless, endovascular thoracic intervention began to be performed in Japan in the early 1990s, with homemade devices used in most cases. Many researchers have continued to develop their homemade devices. We have participated in joint design and assessment efforts with a stent-graft manufacturer, focusing primarily on fenestrated stent-grafts used in repairs at the distal arch, a site especially prone to aneurysm. In March 2008, TAG (W.L. Gore & Associates, Inc., Flagstaff, Arizona, USA) was approved as a stent graft for the thoracic area first in Japan, which was major turning point in treatment for thoracic aortic aneurysms. Subsequently, TALENT (Medtronic, Inc., Minneapolis, Minnesota, USA) was approved in May 2009, and TX2 (COOK MEDICAL Inc., Bloomington, Indiana, USA) in March 2011. Valiant as an improved version of TALENT was approved in November 2011, and TX2 Proform as an improved version of TX2 began to be supplied in October 2012. These stent grafts are excellent devices that showed good results in Western countries, and marked effectiveness can be expected by making the most of the characteristics of each device. A clinical trial in Japan on Najuta (tentative name) (Kawasumi Labo., Inc., Tokyo, Japan) as a line-up of fenestrated stent grafts that can be applied to distal arch aneurysms showing a high incidence, and allow maintenance of blood flow to the arch vessel was initiated. This trial was completed, and Najuta has just been approved in January of 2013 in Japan, and further development is expected. In the U.S., great efforts have recently been made to develop and manufacture excellent stent grafts for thoracic aneurysms, and rapid progress has been achieved. In particular, in the area of the aortic arch, in which we often experience aneurysmal change, but there are no commercially available devices which are urgently needed. Companies are competing keenly to develop devices. To our knowledge, more than 4 manufacturers are involved in the development of functionally new stent grafts in this area. The introduction of branched stent grafts may not be faraway.

Verified
Journal Article
Open access
PDF file
NTNaomichi Tanaka
Naomichi Tanaka
HKHidemasa Kato
Hidemasa Kato
HTHiromi Tsuda
Hiromi Tsuda
YSYasunori Sato
Yasunori Sato
TMToshihiro Muramatsu
Toshihiro Muramatsu
Takaaki SenbonmatsuTakaaki Senbonmatsu
Takaaki Senbonmatsu
Induced pluripotent stem (iPS) cells are a type of artificial pluripotent stem cell induced by the epigenetic silencing of somatic cells by the Yamanaka factors. Advances in iPS cell reprogramming technology will allow aging or damaged cells to be replaced by a patient’s own rejuvenated cells. However, tissue that is senescent or pathologic has a relatively low reprogramming efficiency as compared with juvenile or robust tissue, resulting in incomplete reprogramming; iPS cells generated from such tissue types do not have sufficient differentiation ability and are therefore difficult to apply clinically. Here, we develop a new reprogramming method and examine it using myofibroblasts, which are pathologic somatic cells, from patient skin tissue and from each of the four heart chambers of a recipient heart in heart transplant surgery. By adjusting the type and amount of vectors containing transcriptional factors for iPS cell reprogramming, as well as adjusting the transfection load and culture medium, the efficiency of iPS cell induction from aged patient skin-derived fibroblasts was increased, and we successfully induced iPS cells from myocardial fibroblasts isolated from the pathologic heart of a heart transplant recipient.